An exploration of the prevalence and experience of cardiac cachexia: protocol for a mixed methods cross-sectional study.
Cachexia
Cardiac cachexia
Cross-sectional study
Heart failure
Mixed methods
Palliative care
Journal
BMC palliative care
ISSN: 1472-684X
Titre abrégé: BMC Palliat Care
Pays: England
ID NLM: 101088685
Informations de publication
Date de publication:
20 Oct 2019
20 Oct 2019
Historique:
received:
19
06
2019
accepted:
24
09
2019
entrez:
22
10
2019
pubmed:
22
10
2019
medline:
14
4
2020
Statut:
epublish
Résumé
Cachexia is a complex and multifactorial syndrome defined as severe weight loss and muscle wasting which frequently goes unrecognised in clinical practice [1]. It is a debilitating syndrome, resulting in patients experiencing decreased quality of life and an increased risk of premature death; with cancer cachexia alone resulting in 2 million deaths per annum [2]. Most work in this field has focused on cancer cachexia, with cardiac cachexia being relatively understudied - despite its potential prevalence and impact in patients who have advanced heart failure. We report here the protocol for an exploratory study which will: 1. focus on determining the prevalence and clinical implications of cardiac cachexia within advanced heart failure patients; and 2. explore the experience of cachexia from patients' and caregivers' perspectives. A mixed methods cross-sectional study. Phase 1: A purposive sample of 362 patients with moderate to severe heart failure from two Trusts within the United Kingdom will be assessed for known characteristics of cachexia (loss of weight, loss of muscle, muscle mass/strength, anorexia, fatigue and selected biomarkers), through basic measurements (i.e. mid-upper arm circumference) and use of three validated questionnaires; focusing on fatigue, quality of life and appetite. Phase 2: Qualitative semi-structured interviews with patients (n = 12) that meet criteria for cachexia, and their caregivers (n = 12), will explore their experience of this syndrome and its impact on daily life. Interviews will be digitally recorded and transcribed verbatim, prior to qualitative thematic and content analysis. Phase 3: Workshops with key stakeholders (patients, caregivers, healthcare professionals and policy makers) will be used to discuss study findings and identify practice implications to be tested in further research. Data collected as part of this study will allow the prevalence of cardiac cachexia in a group of patients with moderate to severe heart failure to be determined. It will also provide a unique insight into the implications and personal experience of cardiac cachexia for both patients and carers. It is hoped that robust quantitative data and rich qualitative perspectives will promote crucial clinical discussions on implications for practice, including targeted interventions to improve patients' quality of life where appropriate.
Sections du résumé
BACKGROUND
BACKGROUND
Cachexia is a complex and multifactorial syndrome defined as severe weight loss and muscle wasting which frequently goes unrecognised in clinical practice [1]. It is a debilitating syndrome, resulting in patients experiencing decreased quality of life and an increased risk of premature death; with cancer cachexia alone resulting in 2 million deaths per annum [2]. Most work in this field has focused on cancer cachexia, with cardiac cachexia being relatively understudied - despite its potential prevalence and impact in patients who have advanced heart failure. We report here the protocol for an exploratory study which will: 1. focus on determining the prevalence and clinical implications of cardiac cachexia within advanced heart failure patients; and 2. explore the experience of cachexia from patients' and caregivers' perspectives.
METHODS
METHODS
A mixed methods cross-sectional study. Phase 1: A purposive sample of 362 patients with moderate to severe heart failure from two Trusts within the United Kingdom will be assessed for known characteristics of cachexia (loss of weight, loss of muscle, muscle mass/strength, anorexia, fatigue and selected biomarkers), through basic measurements (i.e. mid-upper arm circumference) and use of three validated questionnaires; focusing on fatigue, quality of life and appetite. Phase 2: Qualitative semi-structured interviews with patients (n = 12) that meet criteria for cachexia, and their caregivers (n = 12), will explore their experience of this syndrome and its impact on daily life. Interviews will be digitally recorded and transcribed verbatim, prior to qualitative thematic and content analysis. Phase 3: Workshops with key stakeholders (patients, caregivers, healthcare professionals and policy makers) will be used to discuss study findings and identify practice implications to be tested in further research.
DISCUSSION
CONCLUSIONS
Data collected as part of this study will allow the prevalence of cardiac cachexia in a group of patients with moderate to severe heart failure to be determined. It will also provide a unique insight into the implications and personal experience of cardiac cachexia for both patients and carers. It is hoped that robust quantitative data and rich qualitative perspectives will promote crucial clinical discussions on implications for practice, including targeted interventions to improve patients' quality of life where appropriate.
Identifiants
pubmed: 31630685
doi: 10.1186/s12904-019-0471-0
pii: 10.1186/s12904-019-0471-0
pmc: PMC6802347
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
82Subventions
Organisme : Northern Ireland Chest Heart and Stroke
ID : NICHS 2018_08
Références
Card Fail Rev. 2017 Apr;3(1):7-11
pubmed: 28785469
Eur Heart J. 2016 Jun 1;37(21):1684-91
pubmed: 26865478
Eur Heart J. 2016 Jul 14;37(27):2129-2200
pubmed: 27206819
Eur J Heart Fail. 2016 Jul;18(7):786-95
pubmed: 26821594
Int J Cardiol. 1999 Sep 30;71(1):79-84
pubmed: 10522568
J Am Coll Cardiol. 2014 Sep 30;64(13):1388-400
pubmed: 25257642
Endocrine. 2013 Jun;43(3):626-34
pubmed: 23179776
Nurs Health Sci. 2013 Sep;15(3):398-405
pubmed: 23480423
Lancet. 1997 Apr 12;349(9058):1050-3
pubmed: 9107242
Int J Obes Relat Metab Disord. 2002 Jul;26(7):953-60
pubmed: 12080449
Eval Health Prof. 2005 Jun;28(2):172-91
pubmed: 15851772
Respir Med. 2011 Jan;105(1):57-66
pubmed: 20932736
Int J Cardiol. 2011 Feb 3;146(3):359-63
pubmed: 19703717
J Adv Nurs. 2008 Apr;62(1):107-15
pubmed: 18352969
J Cachexia Sarcopenia Muscle. 2013 Sep;4(3):173-8
pubmed: 23539127
Lancet Oncol. 2011 May;12(5):489-95
pubmed: 21296615
Int J Nurs Stud. 2009 May;46(5):606-16
pubmed: 19081090
Am J Phys Med Rehabil. 2007 Jan;86(1 Suppl):S29-46
pubmed: 17370370
Int J Cardiol. 2005 Mar 18;99(2):239-45
pubmed: 15749182
Pharmacol Ther. 2009 Mar;121(3):227-52
pubmed: 19061914
Clin Nutr. 2017 Jun;36(3):910-911
pubmed: 28238466
Eur J Heart Fail. 2018 Nov;20(11):1580-1587
pubmed: 30160804
J Cachexia Sarcopenia Muscle. 2014 Dec;5(4):253-9
pubmed: 25425503
J Adv Nurs. 2004 Jun;46(5):514-22
pubmed: 15139940
J Cachexia Sarcopenia Muscle. 2014 Dec;5(4):261-3
pubmed: 25384990
Circ Res. 2013 Aug 30;113(6):646-59
pubmed: 23989710
Eur J Cancer Care (Engl). 2010 Sep;19(5):682-9
pubmed: 19912306
Clin Nutr. 2010 Apr;29(2):154-9
pubmed: 20060626
J Support Oncol. 2005 Sep-Oct;3(5):377-82
pubmed: 16218262
Support Care Cancer. 2009 Feb;17(2):129-35
pubmed: 18386071
Eur J Heart Fail. 2015 Apr;17(4):424-33
pubmed: 25704364
Qual Life Res. 2000;9(10):1137-46
pubmed: 11401046
Int J Cardiol. 2013 Nov 5;169(3):219-24
pubmed: 24063924
Lancet. 2003 Mar 29;361(9363):1077-83
pubmed: 12672310
J Ren Care. 2015 Jun;41(2):79-80
pubmed: 25982191
Curr Opin Support Palliat Care. 2014 Dec;8(4):334-8
pubmed: 25144837
Clin Nutr. 2009 Aug;28(4):455-60
pubmed: 19515464
J Appl Physiol (1985). 2013 May;114(9):1253-62
pubmed: 23019314
Ann Oncol. 2005 Dec;16(12):1949-55
pubmed: 16227316
Am J Clin Nutr. 2005 Nov;82(5):1074-81
pubmed: 16280441
J Cachexia Sarcopenia Muscle. 2014 Sep;5(3):171-6
pubmed: 25192875
Eur Heart J. 2013 Jan;34(1):30-8
pubmed: 22297124
J Clin Oncol. 2003 Dec 1;21(23):4439-43
pubmed: 14645434
J Gerontol A Biol Sci Med Sci. 2000 Mar;55(3):M168-73
pubmed: 10795731
J Cachexia Sarcopenia Muscle. 2013 Sep;4(3):199-207
pubmed: 23483531
Eur J Clin Nutr. 2013 Aug;67(8):797-801
pubmed: 23820338
Support Care Cancer. 2012 Nov;20(11):2639-47
pubmed: 22544223
J Adv Nurs. 2002 Feb;37(3):273-81
pubmed: 11851798